Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771818 | 0.83 | ESR1 (0.46) | ESR1ESR2CYP1A2TSHRTLR8 | |
| SCHEMBL1206773 | 0.83 | ESR1 (0.72) | ESR1ESR2CYP1A2TLR8CYP3A4 | |
| SCHEMBL17445867 | 0.83 | ESR1 (0.46) | ESR1ESR2CYP1A2TSHRTLR8 | |
| SCHEMBL30219728 | 0.79 | ESR1 (0.49) | ESR1ESR2CYP1A2TLR8LMNA | |
| SCHEMBL13296157 | 0.79 | ESR1 (0.49) | ESR1ESR2CYP1A2TSHRTLR8 | |
| SCHEMBL24717188 | 0.79 | ESR1 (0.43) | ESR1ESR2CYP1A2TSHRTLR8 | |
| SCHEMBL19680603 | 0.79 | LMNA (0.66) | ESR1ESR2CYP1A2TSHRTLR8 | |
| SCHEMBL1533447 | 0.78 | CYP1A2 (0.57) | ESR1ESR2CYP1A2TSHRLMNA | |
| SCHEMBL599166 | 0.77 | ALDH1A1 (0.63) | ESR1ESR2CYP1A2TSHRCYP2A6 | |
| SCHEMBL8078744 | 0.76 | ESR1 (0.49) | ESR1ESR2MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344080-B2 | Catalyst for olefin polymerization and method of preparation thereof | WANG LICAI (CN) | 2013-01-01 | — | — | US | disclosed |
| US-20110301385-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD OF PREPARATION THEREOF | WANG LICAI (CN) | 2011-12-08 | — | — | US | disclosed |
| US-7964678-B2 | Comprises titanium/magnesium-1,4-diether [2,2'-dialkoxy-1,1'-biphenyl, 2,2'-dialkoxy-1,1'-binaphthalene, 10,10'-dialkoxy-9,9-biphenanthrene complex, organoaluminum compound, and organosilicon compound; molecular weight control | WANG LICAI | 2011-06-21 | — | — | US | disclosed |
| US-20080161513-A1 | Catalyst for Olefin Polymerization and Preparation Thereof and Polymerization Process | YINGKOU XIANGYANG CATALYST CO., LTD. (CN) | 2008-07-03 | — | — | US | disclosed |
| US-7192779-B1 | Diagnosis of Smith-Lemli-Optiz syndrome | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301385-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD OF PREPARATION THEREOF | PPOX, CAT, POR | ESR1 2315/4885ESR2 3033/4885CYP1A2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.